Inhibition of rho kinase enhances survival of dopaminergic neurons and attenuates axonal loss in a mouse model of Parkinson's disease

Brain

Volumn 135, Issue 11, 2012, Pages 3355-3370

  Tönges, Lars ^a   Frank, Tobias ^a   Tatenhorst, Lars ^a   Saal, Kim A ^a   Koch, Jan C ^a   Szego, Éva M ^b,c   Bähr, Mathias ^a,b   Weishaupt, Jochen H ^d   Lingor, Paul ^a,b  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b Center for Nanoscale Microscopy and Molecular Physiology of the Brain (CNMPB)   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d UNIVERSITY OF ULM   (Germany)

Author keywords

1 methyl 4 phenyl 1,2,3,6 tetrahydropyridine; axonal degeneration; dopaminergic cell death; Parkinson's disease; rho kinase

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; FASUDIL; RHO KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CULTURE; CELL SURVIVAL; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; ENZYME INHIBITION; IN VITRO STUDY; IN VIVO STUDY; MALE; MOTOR PERFORMANCE; MOUSE; NERVE FIBER DEGENERATION; NEURITE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL;

EID: 84870198515     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/aws254     Document Type: Article

References (67)

1. Abe K, Shimokawa H, Morikawa K, Uwatoku T, Oi K, Matsumoto Y, et al. Long-Term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ Res 2004; 94: 385-93.
2. Altar CA, Boylan CB, Jackson C, Hershenson S, Miller J, Wiegand SJ, et al. Brain-derived neurotrophic factor augments rotational behavior and nigrostriatal dopamine turnover in vivo. Proc Natl Acad Sci U S A 1992; 89: 11347-51.
3. Andringa G, Eshuis S, Perentes E, Maguire RP, Roth D, Ibrahim M, et al. TCH346 prevents motor symptoms and loss of striatal FDOPA uptake in bilaterally MPTP-Treated primates. Neurobiol Dis 2003; 14: 205-17.
4. Beal MF, Matthews RT, Tieleman A, Shults CW. Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice. Brain Res 1998; 783: 109-14.
5. Benazzouz A, Boraud T, Dubedat P, Boireau A, Stutzmann JM, Gross C. Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study. Eur J Pharmacol 1995; 284: 299-307.
6. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 1973; 20: 415-55.
7. Borisoff JF, Chan CC, Hiebert GW, Oschipok L, Robertson GS, Zamboni R, et al. Suppression of Rho-kinase activity promotes axonal growth on inhibitory CNS substrates. Mol Cell Neurosci 2003; 22: 405-16.
8. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-211.
9. Burke RE. Intracellular signalling pathways in dopamine cell death and axonal degeneration. Prog Brain Res 2010; 183: 79-97.
10. Burke RE, O'Malley K. Axon degeneration in Parkinson's disease. Exp Neurol 2012; [Epub ahead of print].
11. Cannon JR, Greenamyre JT. Neurotoxic in vivo models of Parkinson's disease recent advances. Prog Brain Res 2010; 184: 17-33.
12. Cheng HC, Ulane CM, Burke RE. Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol 2010; 67: 715-25.
13. Cheng HC, Kim SR, Oo TF, Kareva T, Yarygina O, Rzhetskaya M, et al. Akt suppresses retrograde degeneration of dopaminergic axons by inhibition of macroautophagy. J Neurosci 2011; 31: 2125-35.
14. Coleman M. Axon degeneration mechanisms: commonality amid diversity. Nat Rev Neurosci 2005; 6: 889-98.
15. Coleman MP, Perry VH. Axon pathology in neurological disease: a neglected therapeutic target. Trends Neurosci 2002; 25: 532-7. (Pubitemid 35246324)
16. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003; 39: 889-909.
17. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000; 351: 95-105.
18. Dehmer T, Heneka MT, Sastre M, Dichgans J, Schulz JB. Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J Neurochem 2004; 88: 494-501.
19. Frank T, Klinker F, Falkenburger BH, Laage R, Luhder F, Goricke B, et al. Pegylated granulocyte colony-stimulating factor conveys long-Term neuroprotection and improves functional outcome in a model of Parkinson's disease. Brain 2012; 135: 1914-25.
20. Gallo G. Myosin II activity is required for severing-induced axon retraction in vitro. Exp Neurol 2004; 189: 112-21.
21. Greggio E, Cookson MR. Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions. ASN Neuro 2009. 1 pii: e00002.
22. Hashimoto R, Nakamura Y, Kosako H, Amano M, Kaibuchi K, Inagaki M, et al. Distribution of Rho-kinase in the bovine brain. Biochem Biophys Res Commun 1999; 263: 575-9. (Pubitemid 29467237)
23. Herkenham M, Little MD, Bankiewicz K, Yang SC, Markey SP, Johannessen JN. Selective retention of MPP + within the monoaminergic systems of the primate brain following MPTP administration: an in vivo autoradiographic study. Neuroscience 1991; 40: 133-58.
24. Kim SR, Ries V, Cheng HC, Kareva T, Oo TF, Yu WH, et al. Age and alpha-synuclein expression interact to reveal a dependence of dopaminergic axons on endogenous Akt/PKB signaling. Neurobiol Dis 2011a; 44: 215-22.
25. Kim SR, Chen X, Oo TF, Kareva T, Yarygina O, Wang C, et al. Dopaminergic pathway reconstruction by Akt/Rheb-induced axon regeneration. Ann Neurol 2011b; 70: 110-20.
26. Kim SR, Kareva T, Yarygina O, Kholodilov N, Burke RE. AAV transduction of dopamine neurons with constitutively active Rheb protects from neurodegeneration and mediates axon regrowth. Mol Ther 2012; 20: 275-86.
27. Komagome R, Kimura K, Saito M. Postnatal changes in Rho and Rhorelated proteins in the mouse brain. Jpn J Vet Res 2000; 47: 127-33.
28. Kramer ML, Schulz-Schaeffer WJ. Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci 2007; 27: 1405-10.
29. Lang AE. Neuroprotection in Parkinson's disease: and now for something completely different? Lancet Neurol 2006; 5: 990-1. (Pubitemid 44709971)
30. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-Analog synthesis. Science 1983; 219: 979-80.
31. Lees AJ, Hardy J, Revesz T. Parkinson's disease. Lancet 2009; 373: 2055-66.
32. Lehmann M, Fournier A, Selles-Navarro I, Dergham P, Sebok A, Leclerc N, et al. Inactivation of Rho signaling pathway promotes CNS axon regeneration. J Neurosci 1999; 19: 7537-47.
33. Li LH, Qin HZ, Wang JL, Wang J, Wang XL, Gao GD. Axonal degeneration of nigra-striatum dopaminergic neurons induced by 1-methyl-4-phenyl-1,2,3,6- Tetrahydropyridine in mice. J Int Med Res 2009; 37: 455-63.
34. Lingor P, Unsicker K, Krieglstein K. Midbrain dopaminergic neurons are protected from radical induced damage by GDF-5 application. Short communication. J Neural Transm 1999; 106: 139-44.
35. Lingor P, Teusch N, Schwarz K, Mueller R, Mack H, Bahr M, et al. Inhibition of Rho kinase (ROCK) increases neurite outgrowth on chondroitin sulphate proteoglycan in vitro and axonal regeneration in the adult optic nerve in vivo. J Neurochem 2007; 103: 181-9. (Pubitemid 47404219)
36. Lingor P, Tonges L, Pieper N, Bermel C, Barski E, Planchamp V, et al. ROCK inhibition and CNTF interact on intrinsic signalling pathways and differentially regulate survival and regeneration in retinal ganglion cells. Brain 2008; 131: 250-63.
37. Lingor P, Liman J, Kallenberg K, Sahlmann CO, Bähr M. Rana A, editor. Parkinson's Disease /Book 1. Vienna: InTech Open Access Company; 2011.
38. Loirand G, Pacaud P. The role of Rho protein signaling in hypertension. Nat Rev Cardiol 2010; 7: 637-47.
39. Malagelada C, Jin ZH, Greene LA. RTP801 is induced in Parkinson's disease and mediates neuron death by inhibiting Akt phosphorylation/activation. J Neurosci 2008; 28: 14363-71.
40. Mueller BK, Mack H, Teusch N. Rho kinase, a promising drug target for neurological disorders. Nat Rev Drug Discov 2005; 4: 387-98.
41. Muralikrishnan D, Mohanakumar KP. Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-Tetrahydropyridine-induced neurotoxicity in mice. FASEB J 1998; 12: 905-12.
42. Muroyama A, Kobayashi S, Mitsumoto Y. Loss of striatal dopaminergic terminals during the early stage in response to MPTP injection in C57BL/6 mice. Neurosci Res 2011; 69: 352-5.
43. Nagel F, Falkenburger BH, Tonges L, Kowsky S, Poppelmeyer C, Schulz JB, et al. Tat-Hsp70 protects dopaminergic neurons in midbrain cultures and in the substantia nigra in models of Parkinson's disease. J Neurochem 2008; 105: 853-64.
44. Nohria A, Grunert ME, Rikitake Y, Noma K, Prsic A, Ganz P, et al. Rho kinase inhibition improves endothelial function in human subjects with coronary artery disease. Circ Res 2006; 99: 1426-32.
45. Olanow CW, Schapira AH, LeWitt PA, Kieburtz K, Sauer D, Olivieri G, et al. TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 2006; 5: 1013-20.
46. Olanow CW, Kieburtz K, Schapira AH. Why have we failed to achieve neuroprotection in Parkinson's disease? Ann Neurol 2008; 64 (Suppl 2): S101-10.
47. Perry TL, Yong VW, Clavier RM, Jones K, Wright JM, Foulks JG, et al. Partial protection from the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6- Tetrahydropyridine by four different antioxidants in the mouse. Neurosci Lett 1985; 60: 109-14.
48. Przedborski S, Jackson-Lewis V, Yokoyama R, Shibata T, Dawson VL, Dawson TM. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6- Tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc Natl Acad Sci U S A 1996; 93: 4565-71.
49. Przedborski S, Jackson-Lewis V, Naini AB, Jakowec M, Petzinger G, Miller R, et al. The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-Tetrahydropyridine (MPTP): a technical review of its utility and safety. J Neurochem 2001; 76: 1265-74.
50. Raff MC, Whitmore AV, Finn JT. Axonal self-destruction and neurodegeneration. Science 2002; 296: 868-71.
51. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008; 22: 659-61.
52. Ries V, Henchcliffe C, Kareva T, Rzhetskaya M, Bland R, During MJ, et al. Oncoprotein Akt/PKB induces trophic effects in murine models of Parkinson's disease. Proc Natl Acad Sci U S A 2006; 103: 18757-62.
53. Saporito MS, Brown EM, Miller MS, Carswell S. CEP-1347/KT-7515, an inhibitor of c-jun N-Terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons in vivo. J Pharmacol Exp Ther 1999; 288: 421-7. (Pubitemid 29119647)
54. Schallert T, Fleming SM, Leasure JL, Tillerson JL, Bland ST. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 2000; 39: 777-87.
55. Schulz JB, Henshaw DR, Matthews RT, Beal MF. Coenzyme Q10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity. Exp Neurol 1995; 132: 279-83.
56. Storch A, Jost WH, Vieregge P, Spiegel J, Greulich W, Durner J, et al. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. Arch Neurol 2007; 64: 938-44.
57. Strickland D, Bertoni JM. Parkinson's prevalence estimated by a state registry. Mov Disord 2004; 19: 318-23.
58. Szego EM, Gerhardt E, Kermer P, Schulz JB. A30P alpha-synuclein impairs dopaminergic fiber regeneration and interacts with L-DOPA replacement in MPTP-Treated mice. Neurobiol Dis 2012; 45: 591-600.
59. Tonges L, Planchamp V, Koch JC, Herdegen T, Bahr M, Lingor P. JNK isoforms differentially regulate neurite growth and regeneration in dopaminergic neurons in vitro. J Mol Neurosci 2011a; 45: 284-93.
60. Tonges L, Koch JC, Bahr M, Lingor P. ROCKing regeneration: rho kinase inhibition as molecular target for neurorestoration. Front Mol Neurosci 2011b; 4: 39.
61. Tura A, Schuettauf F, Monnier PP, Bartz-Schmidt KU, Henke-Fahle S. Efficacy of Rho-kinase inhibition in promoting cell survival and reducing reactive gliosis in the rodent retina. Invest Ophthalmol Vis Sci 2009; 50: 452-61.
62. Vila M, Przedborski S. Targeting programmed cell death in neurodegenerative diseases. Nat Rev Neurosci 2003; 4: 365-75.
63. Volpicelli-Daley LA, Luk KC, Patel TP, Tanik SA, Riddle DM, Stieber A, et al. Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 2011; 72: 57-71.
64. Wu DC, Teismann P, Tieu K, Vila M, Jackson-Lewis V, Ischiropoulos H, et al. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6- Tetrahydropyridine model of Parkinson's disease. Proc Natl Acad Sci U S A 2003; 100: 6145-50.
65. Zhang Z, Ottens AK, Larner SF, Kobeissy FH, Williams ML, Hayes RL, et al. Direct Rho-Associated kinase inhibition [correction of inhibition] induces cofilin dephosphorylation and neurite outgrowth in PC-12 cells. Cell Mol Biol Lett 2006; 11: 12-29.
66. Zhao J, Zhou D, Guo J, Ren Z, Zhou L, Wang S, et al. Effect of fasudil hydrochloride, a protein kinase inhibitor, on cerebral vasospasm and delayed cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage. Neurol Med Chir (Tokyo) 2006; 46: 421-8.
67. Zou L, Xu J, Jankovic J, He Y, Appel SH, Le W. Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-Tetrahydropyridine in C57BL/6 mice. Neurosci Lett 2000; 281: 167-70.